These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 27854207)

  • 21. Postoperative malignant hyperthermia confirmed by calcium-induced calcium release rate after breast cancer surgery, in which prompt recognition and immediate dantrolene administration were life-saving: a case report.
    Miyazaki N; Kobayashi T; Komiya T; Okada T; Ishida Y; Fukui H; Ogihara Y; Uchino H
    J Med Case Rep; 2021 Apr; 15(1):201. PubMed ID: 33863374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene.
    Cherednichenko G; Ward CW; Feng W; Cabrales E; Michaelson L; Samso M; López JR; Allen PD; Pessah IN
    Mol Pharmacol; 2008 Apr; 73(4):1203-12. PubMed ID: 18171728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis.
    de Lima Silva EV; Donis KC; Machado FRC; Simão Medeiros L; Aschoff CAM; de Souza CFM; Poswar FO; Saute JAM
    J Neuromuscul Dis; 2023; 10(6):1145-1149. PubMed ID: 37781817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle.
    Palnitkar SS; Mickelson JR; Louis CF; Parness J
    Biochem J; 1997 Sep; 326 ( Pt 3)(Pt 3):847-52. PubMed ID: 9307036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Clinical implications.
    Nelson TE; Lin M; Zapata-Sudo G; Sudo RT
    Anesthesiology; 1996 Jun; 84(6):1368-79. PubMed ID: 8669678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term oral Dantrolene Improved Muscular Symptoms in a Malignant Hyperthermia Susceptible Individual.
    Butala BN; Kang A; Guron J; Brandom BW
    J Neuromuscul Dis; 2016 Mar; 3(1):115-119. PubMed ID: 27854207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dantrolene. Pharmacological and therapeutic aspects].
    Gerbershagen MU; Fiege M; Krause T; Agarwal K; Wappler F
    Anaesthesist; 2003 Mar; 52(3):238-45. PubMed ID: 12666006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant hyperthermia.
    Denborough M
    Lancet; 1998 Oct; 352(9134):1131-6. PubMed ID: 9798607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant hyperthermia.
    Ali SZ; Taguchi A; Rosenberg H
    Best Pract Res Clin Anaesthesiol; 2003 Dec; 17(4):519-33. PubMed ID: 14661655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dantrolene--a review of its pharmacology, therapeutic use and new developments.
    Krause T; Gerbershagen MU; Fiege M; Weisshorn R; Wappler F
    Anaesthesia; 2004 Apr; 59(4):364-73. PubMed ID: 15023108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.
    Ward A; Chaffman MO; Sorkin EM
    Drugs; 1986 Aug; 32(2):130-68. PubMed ID: 3527659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease.
    Shi Y; Wang Y; Wei H
    CNS Neurol Disord Drug Targets; 2019; 18(9):668-676. PubMed ID: 29921212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant hyperthermia: clinical and molecular aspects.
    Correia AC; Silva PC; da Silva BA
    Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Malignant hyperthermia].
    Metterlein T; Schuster F; Graf BM; Anetseder M
    Anaesthesist; 2014 Dec; 63(12):908-18. PubMed ID: 25384957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ryanodex--A New Dantrolene Formulation for Malignant Hyperthermia.
    Med Lett Drugs Ther; 2015 Jul; 57(1472):100. PubMed ID: 26147894
    [No Abstract]   [Full Text] [Related]  

  • 37. Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia.
    Litman RS; Smith VI; Larach MG; Mayes L; Shukry M; Theroux MC; Watt S; Wong CA
    Anesth Analg; 2019 Apr; 128(4):652-659. PubMed ID: 30768455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the skeletal muscle ryanodine receptor gene in malignant hyperthermia.
    MacLennan DH; Otsu K; Fujii J; Zorzato F; Phillips MS; O'Brien PJ; Archibald AL; Britt BA; Gillard EF; Worton RG
    Symp Soc Exp Biol; 1992; 46():189-201. PubMed ID: 1341035
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.